Latest stories on VTGN
Vistagen selects GATC Health to apply predictive AI to drug development
The Fly58 · neutralproduct/pr
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
Business Insider58 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen presents data on fasedienol nasal spray at Psych Congress 2026
The Fly59 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Business Insider67 · bullishproduct/pr
VTGN rises after fasedienol open-label extension shows 1.6% AE discontinuation and LSAS improvement through Month 4
September 23, 2026
MarketChameleon67 · bullishproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen announces preliminary data from OLE of Palisade-4 Phase 3 study
The Fly59 · neutralproduct/pr
VistaGen Stockholders Reaffirm Board, Governance and Oversight
TipRanks50 · neutralgeneral
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen to Present at Psych Congress 2026
Business Insider56 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M
Seeking Alpha63 · neutralearnings
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
GlobeNewswire56 · neutralearnings
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
StockTitan56 · neutralearnings
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K50 · neutralgeneral
Vistagen Announces Topline Results From Fasedienol Repeat Dose Study
The Fly63 · neutralearnings
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
StockTitan63 · neutralproduct/pr
Vistagen Therapeutics, Inc. (VTGN) files 8-K
SEC 8-K34 · bearishgeneral
SRX Global Acquires Stake in Vistagen Therapeutics
Yahoo Top63 · neutralm&a
SRX Global Takes a Strategic Stake in Vistagen Therapeutics—A Fresh Vote of Confidence in Neuroscience Innovation
MarketChameleon63 · neutralm&a
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
Business Insider63 · neutralm&a